Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

Jung, Susanne; Schlenk, Richard F.; Hackenbruch, Christopher; Pinzon, Sandra S. L. Roldan; Bitzer, Michael; Pfluegler, Martin; Walz, Juliane S.; Jung, Gundram; Heitmann, Jonas S.; Salih, Helmut R.

dc.contributor.author	Jung, Susanne
dc.contributor.author	Hackenbruch, Christopher
dc.contributor.author	Bitzer, Michael
dc.contributor.author	Walz, Juliane S.
dc.contributor.author	Jung, Gundram
dc.contributor.author	Heitmann, Jonas S.
dc.contributor.author	Salih, Helmut R.
dc.contributor.author	Pflügler, Martin Sebastian
dc.date.accessioned	2024-07-15T09:31:24Z
dc.date.available	2024-07-15T09:31:24Z
dc.date.issued	2024
dc.identifier.issn	2234-943X
dc.identifier.uri	http://hdl.handle.net/10900/155030
dc.language.iso	en	de_DE
dc.publisher	Lausanne : Frontiers Media Sa	de_DE
dc.relation.uri	http://dx.doi.org/10.3389/fonc.2024.1351901	de_DE
dc.subject.ddc	610	de_DE
dc.title	Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240422000000_00581
utue.personen.roh	Jung, Susanne
utue.personen.roh	Schlenk, Richard F.
utue.personen.roh	Hackenbruch, Christopher
utue.personen.roh	Pinzon, Sandra S. L. Roldan
utue.personen.roh	Bitzer, Michael
utue.personen.roh	Pfluegler, Martin
utue.personen.roh	Walz, Juliane S.
utue.personen.roh	Jung, Gundram
utue.personen.roh	Heitmann, Jonas S.
utue.personen.roh	Salih, Helmut R.
dcterms.isPartOf.ZSTitelID	Frontiers in Oncology	de_DE
dcterms.isPartOf.ZS-Issue	Article 1351901	de_DE
dcterms.isPartOf.ZS-Volume	14	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE